Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
41
days
A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications
AuthorsBrad Jordan; Luke Arbogast; Matthew Clemens; Lihua Huang; Matthew Snyder
Affiliations1. Global Regulatory Affairs Eli Lilly and Company; 2. Eli Lilly and Company
308
days
Safe prescribing of antihypertensive drugs in the elderly and managing the risk of adverse events
AuthorsSiddhant Passey; Maheen Erum; Nandan Patel; Shrey Chopra; Hritvik Jain; Jagriti Jha; Tyler Kingma; Obada Kholoki; Ashwin Pillai; Sai Vikram Alampoondi Venkataramanan; Wilbert Aronow
Affiliations1. University of Connecticut School of Medicine; 2. Lady Hardinge Medical College; 3. All India Institute of Medical Sciences; 4. University College of Medical Sciences and Guru Teg Bahadur Hospital; 5. University of Nebraska Medical Center; 6. Westchester Medical Center and New York Medical College
148
days
Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trials
AuthorsGeorge N. Okoli; Benjamin J. Cowling; Nicole Askin; Diane M. Harper; Paul Van Caeseele
Affiliations1. The University of Hong Kong; 2. University of Michigan; 3. Hong Kong Science and Technology Park, New Territories; 4. University of Manitoba; 5. Cadham Provincial Laboratory
185
days
Chronic sequelae of immune-related adverse events
AuthorsSean Ngo; Jarrett Rong; Raakhi Menon; Carolina Colli Cruz; Anirudha Chatterjee; Rachel Mortan; Hamza Salim; Andres Urias Rivera; Faraz I. Jafri; Devin Garza; Stephanie Kim; Pauline Funchain; Hao Chi Zhang; Ajay Sheshadri; Marc Ernstoff; Tomas Neilan; Thein Hlaing Oo; Eric Roeland; Ata Moshiri; Yinghong Wang
Affiliations1. The University of Texas Houston Health Sciences Center; 2. The University of Texas Medical Branch; 3. The University of Texas MD Anderson Cancer Center; 4. Baylor College of Medicine; 5. Dell Medical School; 6. Stanford Medicine; 7. National Institutes of Health; 8. Massachusetts General Hospital; 9. Oregon Health and Science University; 10. Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine
203
days
GLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world
AuthorsMarella Marassi; Gian Paolo Fadini
Affiliations1. University of Padova; 2. Veneto Institute of Molecular Medicine
116
days
Short-acting beta 2 agonists overuse in asthma: where are we now?
AuthorsSabina Antoniu; Theodor Penisoara
Affiliations1. University of Medicine and Pharmacy, Grigore T Popa Iasi
112
days
Are the current safety measures for the treatment of depression with esketamine sufficient?
AuthorsKyle Valentino; Kayla M. Teopiz; Christine E. Dri; Jennifer Swainson; Yang Jing Zheng; Roger S. McIntyre
Affiliations1. Brain and Cognition Discovery Foundation; 2. University of Toronto; 3. University of Alberta
166
days
Rare irAEs associated with immune checkpoint inhibitor therapy
AuthorsJarrett Rong; Faraz Jafri; Sean Ngo; Anirudha Chatterjee; Maria Julia Moura Nascimento Santos; Devin Garza; Hamza Salim; Raakhi Menon; Rachel Mortan; Andres Caleb Urias Rivera; Hao Chi Zhang; Anisha Patel; Cristhiam Rojas Hernandez; Yuanteng Jeff Li; Ajay Sheshadri; Ashley Aaroe; Afreen Shariff; Bryan Schneider; Anusha Thomas; Yinghong Wang
Affiliations1. The University of Texas Health Sciences Center at Houston McGovern Medical School; 2. The University of Texas Medical Branch; 3. The University of Texas MD Anderson Cancer Center; 4. Baylor College of Medicine; 5. Duke University School of Medicine; 6. University of Michigan Health
94
days
From black box to clear box: explainable AI for next-gen pharmacovigilance
AuthorsNirmala Suryadevara; Vishnu Priya; Sanjay Sharma
Affiliations1. SVKM’s NMIMS (Deemed to be University)
97
days
Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-analysis
AuthorsLexie Bai; Shuyun Lin; Delong Liu; Bingbing Zhang; Lili Liu; Guojun Zhao
Affiliations1. The Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Qingyuan, Guangdong, People’s Republic of China; 2. Dali University
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days